Effects of Pomegranate Extract Supplementation on Cardiovascular Risk Factors and Physical Function in Hemodialysis Patients

Journal of Medicinal Food

Volumn 18, Issue 9, 2015, Pages 941-949

  Wu, Pei Tzu ^a,b   Fitschen, Peter J ^b   Kistler, Brandon M ^b   Jeong, Jin Hee ^b   Chung, Hae Ryong ^b   Aviram, Michael ^c   Phillips, Shane A ^d   Fernhall, Bo ^d   Wilund, Kenneth R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

antioxidant supplementation; cardiovascular disease; chronic kidney disease; oxidative stress; physical function

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; POMEGRANATE EXTRACT; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; C REACTIVE PROTEIN; PLANT EXTRACT; POLYPHENOL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; DRUG EFFECT; DYNAMOMETRY; ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; FITNESS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFLAMMATION; MALE; MUSCLE STRENGTH; OXIDATIVE STRESS; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TONOMETRY; BLOOD; CARDIOVASCULAR DISEASES; CHEMISTRY; DAILY LIFE ACTIVITY; DIETARY SUPPLEMENT; DRUG EFFECTS; KIDNEY DISEASE; LYTHRACEAE; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; RISK FACTOR;

ACTIVITIES OF DAILY LIVING; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; INFLAMMATION; KIDNEY DISEASES; MALE; MIDDLE AGED; MUSCLE STRENGTH; OXIDATIVE STRESS; PHYSICAL FITNESS; PLANT EXTRACTS; POLYPHENOLS; PUNICACEAE; RENAL DIALYSIS; RISK FACTORS;

EID: 84941339418     PISSN: 1096620X     EISSN: 15577600     Source Type: Journal    
DOI: 10.1089/jmf.2014.0103     Document Type: Article

References (61)

1. U.S. Renal Data System USRDS Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, USA, 2010.
2. Levey AS, Eknoyan G: Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant 1999;14:828-833.
3. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 2006;17:2034-2047.
4. Johansen KL: Physical functioning and exercise capacity in patients on dialysis. Adv Ren Replace Ther 1999;6:141-148.
5. Johansen KL, Shubert T, Doyle J, Soher B, Sakkas GK, Kent-Braun JA: Muscle atrophy in patients receiving hemodialysis: Effects on muscle strength, muscle quality, and physical function. Kidney Int 2003;63:291-297.
6. Du J, Hu Z, Mitch WE: Cellular signals activating muscle proteolysis in chronic kidney disease: A two-stage process. Int J Biochem Cell Biol 2005;37:2147-2155.
7. Johansen KL, Chertow GM, da Silva M, Carey S, Painter P: Determinants of physical performance in ambulatory patients on hemodialysis. Kidney Int 2001;60:1586-1591.
8. Lane AD, Wu PT, Kistler B, Fitschen P, Tomayko E, Jeong JH, Chung HR, Yan H, Ranadive SM, Phillips S, Fernhall B, Wilund K: Arterial stiffness and walk time in patients with end-stage renal disease. Kidney Blood Press Res 2013;37:142-150.
9. Bergstrom J: Nutrition and mortality in hemodialysis. J Am Soc Nephrol 1995;6:1329-1341.
10. Caglar K, Hakim RM, Ikizler TA: Approaches to the reversal of malnutrition, inflammation, and atherosclerosis in end-stage renal disease. Nutr Rev 2002;60:378-387.
11. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubina P, Lahera V, Luno J: Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int 2008:S4-S9. DOI: 10.1038/ki.2008.516.
12. Himmelfarb J: Oxidative stress in hemodialysis. Contrib Nephrol 2008;161:132-137.
13. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the american heart association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 2003;108:2154-2169.
14. Bergstrom J, Lindholm B, Lacson E Jr., Owen W Jr., Lowrie EG, Glassock RJ, Ikizler TA, Wessels FJ, Moldawer LL, Wanner C, Zimmermann J: What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 2000;13:163-175.
15. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C: Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2008:CD007176. DOI: 10.1002/14651858. CD007176.
16. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (space): Randomised placebo-controlled trial. Lancet 2000;356:1213-1218.
17. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation 2003;107:992-995.
18. Basu A, Penugonda K: Pomegranate juice: A heart-healthy fruit juice. Nutr Rev 2009;67:49-56.
19. Seeram NP, Aviram M, Zhang Y, Henning SM, Feng L, Dreher M, Heber D: Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the United States. J Agric Food Chem 2008;56:1415-1422.
20. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, Hayek T, Presser D, Fuhrman B: Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to ldl, and platelet aggregation: Studies in humans and in atherosclerotic apolipoprotein e-deficient mice. Am J Clin Nutr 2000;71:1062-1076.
21. Kaplan M, Hayek T, Raz A, Coleman R, Dornfeld L, Vaya J, Aviram M: Pomegranate juice supplementation to atherosclerotic mice reduces macrophage lipid peroxidation, cellular cholesterol accumulation and development of atherosclerosis. J Nutr 2001; 131:2082-2089.
22. Aviram M: Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic Res 2000;33 Suppl:S85-S97.
23. Davidson MH, Maki KC, Dicklin MR, Feinstein SB, Witchger M, Bell M, McGuire DK, Provost JC, Liker H, Aviram M: Effects of consumption of pomegranate juice on carotid intimamedia thickness in men and women at moderate risk for coronary heart disease. Am J Cardiol 2009;104:936-942.
24. Aviram M, Rosenblat M, Gaitini D, Nitecki S, Hoffman A, Dornfeld L, Volkova N, Presser D, Attias J, Liker H, Hayek T: Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and ldl oxidation. Clin Nutr 2004; 23:423-433.
25. Shema-Didi L, Sela S, Ore L, Shapiro G, Geron R, Moshe G, Kristal B: One year of pomegranate juice intake decreases oxidative stress, inflammation, and incidence of infections in hemodialysis patients: A randomized placebo-controlled trial. Free Radic Biol Med 2012;53:297-304.
26. Panza JA, Epstein SE, Quyyumi AA: Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med 1991;325:986-990.
27. Hirai T, Sasayama S, Kawasaki T, Yagi S: Stiffness of systemic arteries in patients with myocardial infarction. A noninvasive method to predict severity of coronary atherosclerosis. Circulation 1989;80:78-86.
28. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ: The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000;525(Pt 1): 263-270.
29. Van Bortel LM, Duprez D, Starmans-Kool MJ, Safar ME, Giannattasio C, Cockcroft J, Kaiser DR, Thuillez C: Clinical applications of arterial stiffness, task force iii: Recommendations for user procedures. Am J Hypertens 2002;15:445-452.
30. Rikli RE: Senior Fitness Test Manual. Human Kinetics, Champaign, IL, 2001.
31. Win T, Jackson A, Groves AM, Sharples LD, Charman SC, Laroche CM: Comparison of shuttle walk with measured peak oxygen consumption in patients with operable lung cancer. Thorax 2006;61:57-60.
32. Prior RL, Hoang H, Gu L, Wu X, Bacchiocca M, Howard L, Hampsch-Woodill M, Huang D, Ou B, Jacob R: Assays for hydrophilic and lipophilic antioxidant capacity (oxygen radical absorbance capacity (orac(fl))) of plasma and other biological and food samples. J Agric Food Chem 2003;51:3273-3279.
33. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Descamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-1313.
34. Gugliucci A, Kinugasa E, Kotani K, Caccavello R, Kimura S: Serum paraoxonase 1 (pon1) lactonase activity is lower in endstage renal disease patients than in healthy control subjects and increases after hemodialysis. Clin Chem Lab Med 49:61-67.
35. Hernandez AF, Gil F, Leno E, Lopez O, Rodrigo L, Pla A: Interaction between human serum esterases and environmental metal compounds. Neurotoxicology 2009;30:628-635.
36. Richter RJ, Jampsa RL, Jarvik GP, Costa LG, Furlong CE: Determination of paraoxonase 1 status and genotypes at specific polymorphic sites. Curr Protoc Toxicol 2004;Chapter 4:Unit4.12. DOI: 10.1002/0471140856.tx0412s19.
37. Aviram M: Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. Eur J Clin Chem Clin Biochem 1996;34:599-608.
38. Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G: Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension. J Cardiovasc Pharmacol 2003;42:453-461.
39. Lassegue B, Griendling KK: Reactive oxygen species in hypertension; an update. Am J Hypertens 2004;17:852-860.
40. Rodrigo R, Gonzalez J, Paoletto F: The role of oxidative stress in the pathophysiology of hypertension. Hypertens Res 2011;34: 431-440.
41. Galley HF, Thornton J, Howdle PD, Walker BE, Webster NR: Combination oral antioxidant supplementation reduces blood pressure. Clin Sci (Lond) 1997;92:361-365.
42. Rodrigo R, Bosco C: Oxidative stress and protective effects of polyphenols: Comparative studies in human and rodent kidney. A review. Comp Biochem Physiol C Toxicol Pharmacol 2006;142: 317-327.
43. Duarte J, Andriambeloson E, Diebolt M, Andriantsitohaina R: Wine polyphenols stimulate superoxide anion production to promote calcium signaling and endothelial-dependent vasodilatation. Physiol Res 2004;53:595-602.
44. Zenebe W, Pechanova O, Andriantsitohaina R: Red wine polyphenols induce vasorelaxation by increased nitric oxide bioactivity. Physiol Res 2003;52:425-432.
45. Kitiyakara C, Wilcox CS: Antioxidants for hypertension. Curr Opin Nephrol Hypertens 1998;7:531-538.
46. Asgary S, Sahebkar A, Afshani MR, Keshvari M, Haghjooyjavanmard S, Rafieian-Kopaei M: Clinical evaluation of blood pressure lowering, endothelial function improving, hypolipidemic and anti-inflammatory effects of pomegranate juice in hypertensive subjects. Phytother Res 2014;28:193-199.
47. Aviram M, Dornfeld L: Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis 2001;158:195-198.
48. Poredos P: Intima-media thickness: Indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med 2004;9:46-54.
49. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C: Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 2001;12:2458-2464.
50. Hauer K, Hildebrandt W, Sehl Y, Edler L, Oster P, Droge W: Improvement in muscular performance and decrease in tumor necrosis factor level in old age after antioxidant treatment. J Mol Med (Berl) 2003;81:118-125.
51. Trombold JR, Barnes JN, Critchley L, Coyle EF: Ellagitannin consumption improves strength recovery 2-3 days after eccentric exercise. Med Sci Sports Exerc 2010;42:493-498.
52. Trombold JR, Reinfeld AS, Casler JR, Coyle EF: The effect of pomegranate juice supplementation on strength and soreness after eccentric exercise. J Strength Cond Res 2011;25:1782-1788.
53. Himmelfarb J, Ikizler TA, Ellis C, Wu P, Shintani A, Dalal S, Kaplan M, Chonchol M, Hakim RM: Provision of antioxidant therapy in hemodialysis (path): A randomized clinical trial. J Am Soc Nephrol 2014;25:623-633.
54. Rock W, Rosenblat M, Miller-Lotan R, Levy AP, Elias M, Aviram M: Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem 2008;56:8704-8713.
55. Rosenblat M, Volkova N, Attias J, Mahamid R, Aviram M: Consumption of polyphenolic-rich beverages (mostly pomegranate and black currant juices) by healthy subjects for a short term increased serum antioxidant status, and the serum's ability to attenuate macrophage cholesterol accumulation. Food Funct 2010;1:99-109.
56. Tavori H, Khatib S, Aviram M, Vaya J: Characterization of the pon1 active site using modeling simulation, in relation to pon1 lactonase activity. Bioorg Med Chem 2008;16:7504-7509.
57. Tavori H, Vaya J, Aviram M: Paraoxonase 1 attenuates human plaque atherogenicity: Relevance to the enzyme lactonase activity. Adv Exp Med Biol 2010;660:99-111.
58. Vos E: Homocysteine levels, paraoxonase 1 (pon1) activity, and cardiovascular risk. JAMA 2008;300:168-169; author reply 169.
59. Seeram NP, Henning SM, Zhang Y, Suchard M, Li Z, Heber D: Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 2006;136:2481-2485.
60. Seeram NP, Zhang Y, McKeever R, Henning SM, Lee RP, Suchard MA, Li Z, Chen S, Thames G, Zerlin A, Nguyen M, Wang D, Dreher M, Heber D: Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J Med Food 2008;11:390-394.
61. Rosenblat M, Hayek T, Aviram M: Anti-oxidative effects of pomegranate juice (pj) consumption by diabetic patients on serum and on macrophages. Atherosclerosis 2006;187:363-371.